Article PDF
References
Allison AC, Eugui EM. The role of cell-mediated immune responses in resistance to malaria, with special reference to oxidant stress. Annual Review of Immunology 1: 361, 1983
Anders RF. Multiple cross-reactivities amongst antigens of Plasmodium falciparum impair the development of protective immunity against malaria. Parasite Immunology 8: 529–539, 1986
Anders RF, Smythe JA, Barzaga NG, Forsyth KP, Brown HJ, et al. Antigenic diversity of the asexual blood stages of Plasmodium falciparum. In McAdam (Ed.) New strategies in parasitology, pp. 19–36, 1989
Arnon R. Synthetic vaccines. In Roit IM (Ed.) New trends in vaccines, Vol. 93, Academic Press, London, 1984
Audibert F, Jolivet M, Chedid L, Arnon R, Sela M. Successful immunization with a totally synthetic diphtheria vaccine. Proceedings of the National Academy of Sciences of the USA 79: 5042–5046, 1982
Ballou WR, Rothbard J, Wirz RA, Gordon DM, Williams JS, et al. Immunogenicity of synthetic peptides from the circumsporozoite protein of Plasmodium falciparum.Science 228: 996–999, 1985
Ballou WR, Hoffman SL, Sherwood JA, Hollingdale MR, Neva FA, et al. Safety and efficacy of recombinant DNA Plasmodium falciparumsporozoite vaccine. Lancet 1: 1277–1280, 1987
Bomford R. The comparative selectivity of adjuvants for humoral and cell-mediated immunity. I. Effect on the antibody response to bovine serum albumin and sheep red blood cells of Freund’s complete and incomplete adjuvants, alhydrogel, Cornybacterium parvum, Bordetella pertussis, muramyl dipeptide and saponin. Clinical and Experimental Immunology 39: 435–441, 1980
Bomford R. Adjuvants for anti-parasitic vaccines. Parasitology Today 5: 41–46, 1989
Brake DA, Weidanz WP, Long CA. Antigen-specific, Interleukin 2-propagated T lymphocytes confer resistance to a murine malarial parasite, Plasmodium chabaudi adami.Journal of Immunology 137: 347–352, 1986
Brake DA, Goldring JPD, Weidanz WP, Long CA. Characterization of cellular and humoral responses of T lymphocytes reconstituted athymic mice infected with Plasmodium chabaudi adami.Federation Proceedings 46: 618–621, 1987
Brown IN. Immunological aspects of malaria infection. Advances in Immunology 11: 267–349, 1969
Brown GV, Culvenor IG, Crewther PE, Bianco AE, Coppel RL, et al. Localization of the ring infected erythrocyte surface antigen (RESA) of Plasmodium falciparumin merozoites and ring infected erythrocytes. Journal of Experimental Medicine 162: 774–779, 1985
Camus D, Hadley TJ. A Plasmodium falciparumantigen that binds to host erythrocytes and merozoites. Science 230: 553–556, 1985
Carter R, Gwadz RW. Infectiousness and gamete immunization in malaria. In Kreier JP (Ed.) Malaria, Vol. 3, Academic Press, New York, 1980
Carter R, Graves PM, Quakyi IA, Good MF. Restricted or absent immune responses in human populations to Plasmodium falciparum gamete antigens that are targets of malaria transmission-blocking antibodies. Journal of Experimental Medicine 169: 135–147, 1989
Chang SP, Kramer KJ, Yamaga KM, Kato A, Case SE, Siddiqui WA. Plasmodium falciparum: gene structure and hydropathy profile of the major merozoite surface antigen (gp195) of the Uganda-Palo Alto isolate. Experimental Parasitology 67: 1–11, 1988
Chang SP, Hui GSN, Kato A, Siddiqui WA. Generalized immunological recognition of the major merozoite surface antigen (gp195) of Plasmodium falciparum.Proceedings of the National Academy of Science 86: 6343–6347, 1989
Cheung A, Leban J, Shaw AR, Merkli B, Stocken J, et al. Immunization with synthetic peptides of a Plasmodium falciparumsurface antigen induced antimerozoite antibodies. Proceedings of the National Academy of Science (USA) 83: 8328–8332, 1986
Chizzolini C, Dupont A, Akue JP, Kaufmann MH, Verdini As, et al. Natural antibodies against three distinct and defined antigens of Plasmodium falciparumin residents of a mesoendemic area in Gabon. American Journal of Tropical Medicine and Hygiene 39: 150–156, 1988
Clark IA, Chaudhri G, Cowden WB. Roles of tumor necrosis factor in the illness and pathology of malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene 83: 436–440, 1989
Clyde DF, Most H, McCarthy V, Vanderberg JP. Immunization of man against sporozoite-induced falciparum malaria. American Journal of Medical Science 266: 169–177, 1973
Cochrane AH, Nussenzweig RS, Nardin EH. Immunization against sporozoites. In Kreier JP (Ed.) Malaria, Vol. 3, Academic Press, New York, 1980
Cohen S, McGregor IA, Carrington SC. Gammaglobulin and acquired immunity to human malaria. Nature 192: 733–735, 1961
Cohen S, Mitchell GH. Prospects for immunisation against malaria. Current Topics in Microbiology and Immunology 80: 97–137, 1978
Collins WE, Anders RF, Pappaioanou M, Brown GV, Kemp DJ, et al. Immunization of Aotusmonkeys with recombinant proteins of an erythrocyte surface antigen of P. falciparum.Nature 323: 259–262, 1986
Crisanti A, Muller H, Hilbich C, Sinigaglia F, Matile H, et al. Epitopes recognized by human T cells map within the conserved part of the GP190 of P. falciparum.Science 240: 1324–1326, 1988
Dame JB, Williams JL, McCutchan TF, Weber JL, Wirtz RA, et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum.Science 225: 593–599, 1984
Del Giudice G, Copper JA, Merino J, Verdini AS, Pessi A, et al. The antibody response in mice to carrier free synthetic polymers of Plasmodium falciparumcircumsporozoite repetitive epitope is I-Abrestricted: possible implications for malaria vaccines. Journal of Immunology 137: 2952–2955, 1986
Del Giudice G, Engers HD, Tougne C, Biro SS, Weiss N, et al. Antibodies to the repetitive epitope of Plasmodium falciparumcircumsporozoite protein in a rural Tanzanian community: a longitudinal study. American Journal of Tropical Medicine and Hygiene 36: 203–212, 1987
Delplace P, Dubremetz JF, Fortner B, Vernes A. A 50 kilodalton exoantigen specific to the merozoite release reinvasion stage of Plasmodium falciparum.Molecular and Biochemical Parasitology 17: 239–251, 1985
Edelman T. Vaccine adjuvants. Review of Infections Research 2: 370–383, 1980
Enea V, Ellis J, Zavala F, Arnot DE, Asanavich A, et al. DNA cloning of Plasmodium falciparumcircumsporozoite gene: amino-acid sequence of repetitive epitope. Science 225: 628–629, 1984
Favaloro JM, Coppel RL, Corcoran LM, Foote SJ, Brown GV, et al. Structure of the RESA gene of Plasmodium falciparum.Nucleic Acid Research 14: 8265–8277, 1986
Gabra MS, Grossiord D, Perrin LH, Shaw A, Cheung A, et al. Defined Plasmodium falciparumantigens in malaria serology. Bulletin World Health Organization 64: 889–896, 1986
Good MF, Berzofsky JA, Maloy WL, Hayashi Y, Fujii N, et al. Genetic control of the immune response in mice to a Plasmodium falciparumsporozoite vaccine: widespread non-responsiveness to single malaria T epitope in highly repetitive vaccine. Journal of Experimental Medicine 164: 655–660, 1986
Good MF, Maloy WL, Lunde MN, Margalit H, Cornette JL, et al. Construction of synthetic immunogen: use of new T-helper epitope on malaria circumsporozoite protein. Science 235: 1059–1062, 1987
Good MF, Pombo D, Quakyi I, Riley EM, Houghten RA, et al. Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule. Proceedings of the National Academy of Sciences of the USA 85: 1199–1203, 1988a
Good MF, Miller LH, Kumar S, Quakyi IA, Keister D, et al. Limited immunological recognition of critical malaria vaccine candidate antigens. Science 242: 574–577, 1988b
Good MF, Rombo D, Lunde MN, Maloy WL, Halenbeck R, et al. Recombinant human IL-2 overcomes genetic non-responsiveness to malaria sporozoite peptides. Journal of Immunology 141: 972–977, 1988c
Grau GE, Fajardo LF, Piquet PF, Allet B, Lamberst PH, Vassali P. Tumor necrosis factor (cachectin) as an essential mediator in m urine cerebral malaria. Science 237: 1210–1212, 1987
Graves PM, Carter R, Burkot TR, Rener J, Kaushal DC, et al. Effects of transmission-blocking monoclonal antibodies on different isolates of Plasmodium falciparum.Infection and Immunity 48: 611–616, 1985
Graves PM, Carter R, Burkot TR, Quakyi IA, Kumar N. Antibodies to Plasmodium falciparumgamete surface antigens in Papua New Guinea sera. Parasite Immunology 10: 209–218, 1988
Hall R, Hyde JE, Goman D, Simmons DL, Hope IA, et al. Major surface antigen gene of a human malaria parasite cloned and expressed in bacteria. Nature 311: 379–382, 1984
Heidrich HG. Plasmodium falciparumantigens as target molecules for a protective immunization against malaria: an up-to-date review. Zeitschrift für Parasitenkunde 72: 1–11, 1986
Herrera S, Herrera MA, Perlaza BL, Burki Y, Caspers P, et al. Immunization of Aotusmonkeys with Plasmodium falciparumblood-stage recombinant proteins. Proceedings of the National Academy of Science (USA) 87: 4017–4021, 1990
Herrington DA, Clyde DF, Losonsky G, Cortesia M, Murphy JR, et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparumsporozoites. Nature 328: 257–259, 1987
Holder AA, Freeman RR. Biosynthesis and processing of a Plasmodium falciparumschizont antigen recognized by immune serum and monoclonal antibody. Journal of Experimental Medicine 156: 1528–1538, 1982
Holder AA, Lockyer MJ, Odink KG, Sandhu JS, Riveros-Moreno V, et al. Primary structure of the precursor to the three major surface antigens of Plasmodiumfalciparummerozoites. Nature 317: 270–273, 1985
Holder AA, Freeman RF, Uni S, Aikawa M. Isolation of a Plasmodiumfalciparumrhoptry protein. Molecular and Biochemical Parasitology 14: 293–303, 1985
Holder AA, Freeman RR, Nicholls SC. Immunization against Plasmodiumfalciparumwith recombinant polypeptides produced in Escherichiacoli.Parasite Immunology 10: 607–617, 1988
Hommel M, Semoff S. Expression and function of erythrocyte-associated surface antigens in malaria. Biology of the Cell 64: 183–208, 1988
Hui GSN, Chang SP, Tarn LQ, Case WE, Hashiro C, et al. Characterization of antibody responses induced by different synthetic adjuvants to the Plasmodiumfalciparummajor merozoite surface precursor protein, gp195. In Chanock TM et al. (Eds) Vaccine 90, pp. 477–484, Cold Spring Laboratory, New York, 1990
Kaslow DC, Quakyi IA, Syin C, Raum MG, Keister DB, et al. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature 333: 74–76, 1988
Kemp DJ, Coppel RL, Anders RF. Repetitive proteins and genes of malaria. Annual Review of Microbiology 41: 181–208, 1987
Klotz FW, Hudson DE, Coon HG, Miller LH. Vaccination induced variation in the 140KD merozoite surface antigen of Plasmodiumknowlesimalaria. Journal of Experimental Medicine 165: 359–367, 1987
Leech JH, Barnwell JW, Miller LH, Howard RJ. Identification of a strain-specific malarial antigen exposed on the surface of Plasmodium falciparum-infected erythrocytes. Journal of Experimental Medicine 159: 1567–1575, 1
Lew AM, Anders RF, Edwards SJ, Langford CJ. Comparison of antibody avidity and titer elicited by peptide as a protein conjugate or as expressed in vaccinia. Immunology 65: 311–314, 1988
Lew AM, Langford CJ, Pye D, Edwards S, Corcoran L, et al. Class II restriction in mice to the malaria candidate vaccine ring infected erythrocyte surface antigen (RESA) as synthetic peptides or as expressed in recombinant vaccinia. Journal of Immunology 142: 4012–4016, 1989
Lockyer MJ, Schwarz RT. Strain variation in the circumsporozoite protein gene of Plasmodiumfalciparum.Molecular and Biochemical Parasitology 22: 101–108, 1987
Lyon JA, Geller RH, Haynes JD, Chulay JD, Weber JL. Epitope map and processing scheme for the 195,000-dalton surface glycoprotein of Plasmodiumfalciparummerozoite deduced from cloned overlapping segments of the gene. Proceedings of the National Academy of Science (USA) 83: 2989–2993, 1986
Mackay M, Goman M, Bone N, Hyde JE, Scaife J, et al. Polymorphism of the precursor for the major surface antigens of Plasmodiumfalciparummerozoites: studies at the genetic level. European Molecular Biology Journal 4: 3823–3829, 1985
Majarian WM, Daly TM, Weidanz WP, Long CA. Passive immunization against murine malaria with an IgG3monoclonal antibody. Journal of Immunology 132: 3131–3137, 1984
Marsh K, Howard RJ. Antigens induced on erythrocytes by Plasmodiumfalciparum: expression of diverse and conserved determinants. Science 231: 150–153, 1986
McBride JS, Newbold CI, Anand R. Polymorphism of a high molecular weight schizont antigen of the human malaria parasite Plasmodiumfalciparum.Journal of Experimental Medicine 161: 160–180, 1985
McPherson GG, Warrell MJ, White NJ, Looaresuwan S, Warrell D. Human cerebral malaria: a quantitative ultrastructural analysis of parasitized erythrocyte sequestration. American Journal of Pathology 119: 385–401, 1985
Mendis KN, Munesinghe YD, Silva NY, Keragalla I, Carter R. Malaria transmision-blocking immunity induced by natural infections of Plasmodiumvivaxin humans. Infection and Immunity 55: 369–372, 1987
Miller LH, David PH, Hadley TJ. Perspectives for malaria vaccination. Philosophical Transactions of the Royal Society, B, 307: 99–115, 1984
Miller L, Good MF. The main obstacle to a malaria vaccine: the malaria parasite. Vaccine 6: 104–106, 1988
Mitchell GH, Butcher GA, Richards WHG, Cohen S. Merozoite vaccination of douroucouli monkeys against falciparum malaria. Lancet 1: 1335–1338, 1977
Mitchell GH. Vaccination against malaria: its plausibility and the present state of research. Vaccine 2: 115–123, 1984
Mitchell GH. An update on candidate malaria vaccines. Parasitology 98 (Suppl.): 29–47, 1989
Nardin EH, Nussenzweig RS, McGregor IA, Bryan JH. Antibodies to sporozoites: their frequent occurrence in individuals living in an area of hyperendemic malaria. Science 206: 597–599, 1979
Nardin EH, Barr PJ, Heimer E, Etlinger HM. Genetic restriction of the murine humoral response to a recombinant Plasmodiumvivaxcircumsporozoite protein. European Journal of Immunology 18: 1119–1122, 1988
Nussenzweig RS, Vanderberg J, Most H, Orton, C. Specificity of protective immunity induced by x-irradiated .Pbergheisporozoites. Nature 222: 488–489, 1969
Nussenzweig RS, Nussenzweig V. Development of sporozoite vaccine. Philosophical Transactions of the Royal Society, B, 307: 117–128,1984
Nussenzweig V, Nussenzweig RS. Development of a sporozoite malaria vaccine. American Journal of Tropical Medicine and Hygiene 35: 678–688, 1986
Patarroyo ME, Romero P, Torres ML, Clavijo P, Moreno A, et al. Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature 328: 629–632, 1987
Patarroyo ME, Amador R, Clavijo P, Moreno A, Guzman F, et al. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodiumfalciparummalaria. Nature 332: 158–160, 1988
Perlmann H, Berzins K, Wahlgren M, Carlsson J, Bjorkman A, et al. Antibodies in malarial sera to parasite antigens in the membrane of erythrocytes infected with early stages of Plasmodiumfalciparum.Journal of Experimental Medicine 159: 1686–1704, 1984
Perlmann P, Wigzell H. Malaria immunology, progress in allergy, Vol. 41, Karger, Basel, 1988
Perlmann P, Berzins K, Perlmann H, Troye-Blomberg M, Wahlgren M, et al. Malaria vaccines: immunogen selection and epitope mapping. Vaccine 6: 183–187, 1988
Perrin L, Dayal R. Immunity to asexual erythrocytic stages of Plasmodiumfalciparum: role of defined antigens in humoral response. Immunological Review 61: 245–270, 1982
Perrin LH, Merkli B, Loche M, Chizzolini C, Smart J, et al. Antimalarial immunity in Saimirimonkeys: immunization with surface components of asexual blood stages. Journal of Experimental Medicine 160: 441–446, 1984
Perrin LH, Simitsek PH, Srivastava I. Development of malaria vaccines. Tropical and Geographical Medicine 40 (Suppl.): 6–21, 1988
Peters W. Malaria vaccination: two steps forward, one backward. British Medical Journal 287: 1089–1090, 1983
Playfair JHL, Taverne J, Bate CAW, DeSouza JB. The malaria vaccine: anti-parasitic or anti-disease? Immunology Today 11: 25–27, 1990
Quakyi IA, Carter R, Rener J, Kumar N, Good MF, et al. The 230-kDa gamete surface protein of Plasmodiumfalciparumis also a target for transmission-blocking antibodies. Journal of Immunology 139: 4213–4217, 1987
Quakyi IA, Otoo LN, Pombo D, Sugars LVY, Menon A, et al. Differential non-responsiveness in humans of candidate Plasmodiumfalciparumvaccine antigens. American Journal of Tropical Medicine and Hygiene 41: 125–134, 1989
Ravetch JV, Kochan J, Perkins M. Isolation of the gene for a glycophorin-binding protein implicated in erythrocyte invasion by a malaria parasite. Science 227: 1593–1597, 1985
Rener J, Graves PM, Carter R, Williams JL, Burkot TR. Target antigens of transmission blocking immunity or gametes of Plasmodiumfalciparum.Journal of Experimental Medicine 158: 976–981, 1983
Richards RL, Hayre MD, Hockmeyer WT, Alving CR. Liposomes, Lipid A, and aluminum hydroxide enhance the immune response to a synthetic malaria sporozoite antigen. Infection and Immunity 56: 682–686, 1988
Roberts DW, Rank RG, Weidanz WP, Finerty JF. Prevention of recrudescent malaria in nude mice by thymic grafting or by treatment with hyperimmune serum. Infection and Immunity 16: 821–826, 1977
Rodriguez MH, Jungery M. A protein on Plasmodiumfalciparwm-infected erythrocytes functions as a transferrin receptor. Nature 324: 388–391, 1986
Romero PJ, Tarn JP, Schlesinger D, Clavijo P, Barr J, et al. Multiple T-helper cell epitopes of the circumsporozoite protein of Plasmodiumberghei.European Journal of Immunology 18: 1951, 1988
Romero P, Maryanski JL, Corradin G, Nussenzweig RS, Nussenzweig V, et al. Cloned cytotoxic T-cells recognize an epitope in the circumsporozoite (CS) protein and protect against malaria. Nature 341: 323–326, 1989
Rosenberg R, Wirtz RA, Lanar DE, Sattabongkot J, Hall T, et al. Circumsporozoite protein heterogeneity in the human malaria parasite Plasmodiumvivax.Science 245: 973–976, 1989
Siddiqui WA. An effective immunization of experimental monkeys against a human malaria parasite, Plasmodiumfalciparum.Science 197: 388–389, 1977
Siddiqui WA. Immunization against asexual blood-inhabiting stages of Plasmodia In Kreier JP (Ed.) Malaria, Vol. 3, Academic Press, New York, 1980
Siddiqui WA, Tarn LQ, Kramer KJ, Hui GSN, Case SE, et al. Merozoite surface coat precursor protein completely protects Aotusmonkeys against Plasmodiumfalciparummalaria. Proceedings of the National Academy of Science (USA) 84: 3014–3018, 1987
Siddiqui WA, Tarn LQ. Role of adjuvants in malaria vaccines. In Masihi KN & Lange W (Eds) Advances in the biosciences, Vol. 68, pp. 293–298, Pergamon Press, 1988
Singh B, Ho M, Looareesuwan S, Mathai E, Warrell DA, Hommel M. Plasmodiumfalciparum: inhibition/ reversal of cytoadherence of Thai isolates to melanoma cells by local immune sera. Clinical and Experimental Immunology 72: 145–150, 1988
Sinigaglia F, Takacs B, Jacot H, Matile H, Pink JRL, et al. Non-polymorphic region of p190, a protein of the Plasmodiumfalciparumerythrocyte stage, contain both T and B cell epitopes. Journal of Immunology 140: 3568–3572, 1988
Tarn JP, Clavijo P, Lu Y, Nussenzweig V, Nussenzweig RS, et al. Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccines against malaria. Journal of Experimental Medicine 171: 299–306, 1990
Trager W, Jensen JB. Human malaria parasites in continuous culture. Science 193: 673–675, 1976
Troye-Blomberg M, Perlmann P. T-cell functions in Pfalciparumand other malarias. Progress in Allergy 41: 253, 1988
Udeinya IJ, Miller LH, McGregor IA, Jensen JB. Plasmodiumfalciparumstrain specific antibodies block binding of infected erythrocytes to amelanomic melanoma cells. Nature 303: 429–431, 1983
Vermeulen AN, Ponnudurai T, Beckers PJA, Verhave JP, Smits MA, et al. Sequential expression of antigens on sexual stages of Plasmodiumfalciparumaccessible to transmission-blocking antibodies in the mosquito. Journal of Experimental Medicine 162: 1460–1476, 1985
Vosika GJ, Barr C, Gilbertson D. Phase-I study of intravenous modified lipid A. Cancer Immunology and Immunotherapy 18: 107–112, 1984
Walliker D. The genetic basis of diversity in malaria parasites. Advances in Parasitology 22: 217–259, 1983
Walliker D. Genetic recombination in malaria parasites. Experimental Parasitology 69: 303–309, 1989
Warrell DA, Looareesuwan S, Warrell MJ, Kasemsarn P, Intar-aprasert R, et al. Dexamethasone proves deleterious in cerebral malaria: a double-blind trial in 1000 comatose patients. New England Journal of Medicine 306: 313, 1982
Weber JL, Leininger WM, Lyon JA. Variation in the gene encoding a major merozoite surface antigen of the human malaria parasite Plasmodium falciparum. Nucleic Acids Research 14: 3311–3323, 1986
Weidanz WP, Long CA. The role of T cells in immunity to malaria. In Perlmann P & Wigzell H (Eds) Malaria immunology, progress in allergy, Vol. 41, pp. 215–252, 1988
Weinbaum FI, Evans CB, Tigelaar RE. An in-vitro assay for T-cell immunity to malaria. Journal of Immunology 116: 1280–1283, 1976
Weiss WR, Sedegah M, Beaudoin RL, Miller LH, Good MF. CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proceedings of the National Academy of Science (USA) 85: 573–576, 1988
Zavala F, Cochrane AH, Nardin EH, Nussenzweig RS, Nussenzweig V. Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identified epitopes. Journal of Experimental Medicine 157: 1947–1957, 1983
Zavala F, Tarn JP, Hollingdale MR, Cochrane AH, Quakyi I, et al. Rationale for the development of a synthetic vaccine against Plasmodium falciparum sporozoites. Science 228: 1436–1440, 1985
Zavala F, Tarn JP, Masuda A. Synthetic peptide for the detection of humoral immunity to Plasmodium falciparum sporozoites. Journal of Immunological Methods 93: 55–61, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Siddiqui, W.A. Where Are We in the Quest for Vaccines for Malaria?. Drugs 41, 1–10 (1991). https://doi.org/10.2165/00003495-199141010-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199141010-00001